
Surgeons across North America are now removing healthy fallopian tubes during routine operations like hysterectomies, and the reason comes down to one surprising fact: most deadly ovarian cancers don’t start in the ovaries at all.
Quick Take
- Research shows many aggressive ovarian cancers actually begin in the fallopian tubes, not the ovaries themselves.
- A large British Columbia study of over 49,000 women found no major safety problems from removing tubes during other surgeries.
- A separate study of nearly 26,000 patients found zero cases of a deadly cancer type where researchers expected about five.
- Major medical groups now back the practice, but call it risk reduction, not guaranteed prevention.
A Shift in Where Ovarian Cancer Actually Starts
For decades, doctors assumed ovarian cancer began in the ovaries. Newer pathology and genetic research changed that picture. Scientists found that the most dangerous and common form, high-grade serous carcinoma, often starts in cells at the far end of the fallopian tube. That discovery turned a once-ignored organ into a target for cancer prevention, even in women who face no special risk and are having surgery for an unrelated reason.
What the Safety Numbers Actually Show
A study of 49,275 women in British Columbia tracked patients who had their tubes removed during another surgery, such as a hysterectomy or sterilization. Researchers found no rise in follow-up doctor visits for infection, surgical problems, lab testing, or imaging within two weeks of going home. The only measurable difference was slightly more pain medication prescribed, a small tradeoff for a procedure performed while the patient is already under anesthesia for something else.
That safety record matters because it answers the practical question patients ask first: does adding this step to an already-planned surgery create new danger. The data suggest it generally does not, at least for the short-term outcomes researchers measured in hysterectomy, sterilization, and related procedures.
The Cancer Numbers That Got Attention
A separate population-based study followed 25,889 people in British Columbia who had opportunistic tube removal. Based on normal population rates, researchers expected about 5.27 cases of serous ovarian cancer in that group. They found zero. That striking gap is why the procedure has drawn national attention from outlets covering women’s health, even though a zero count in one study period does not prove the risk reaches zero for everyone going forward.
What the Government and Medical Groups Say
The National Cancer Institute describes the evidence linking tube removal to lower ovarian cancer risk as limited but consistent across studies. The American College of Obstetricians and Gynecologists goes further, issuing formal guidance that calls opportunistic salpingectomy a reasonable strategy during surgery already planned for another reason. The group is careful to say the procedure can significantly lower risk without claiming it eliminates the disease entirely.
That distinction matters for how patients should think about this option. It is not pitched as a stand-alone surgery for healthy women seeking cancer protection. It is framed as an add-on, something a surgeon raises when a patient is already on the operating table for a hysterectomy, sterilization, or another procedure where the tubes are already accessible.
Why Adoption Still Varies by Hospital
Even with encouraging data, uptake differs widely between hospitals and individual surgeons. Research tracking implementation in British Columbia and Ontario found that awareness, training, and hospital workflow all shape whether a surgeon offers the procedure. In some operating rooms it has become routine. In others, patients never hear it mentioned as an option, simply because the surgeon’s practice habits haven’t caught up with the newer guidance.
Long-term questions remain, including how tube removal affects ovarian function and the timing of menopause over decades, since most available data track short-term surgical outcomes rather than lifetime effects. That open question is worth a conversation with a doctor, not a reason for alarm, given how solid the short-term safety record looks so far. For women already scheduled for pelvic surgery, it has become a question worth asking before the operation, not after.
Sources:
youtube.com, cancer.gov, vch.ca, acod-conf.org













